Perspective on the role of Ozurdex (dexamethasone intravitreal implant) in the management of diabetic macular oedema

Therapeutic Advances in Chronic Disease

Volumn 6, Issue 5, 2015, Pages 234-245

  Mehta, Hemal ^a   Gillies, Mark ^a   Fraser Bell, Samantha ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Dexamethasone implant; Diabetic macular oedema; Pharmacotherapy

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE; FENOFIBRATE; FLUOCINOLONE ACETONIDE; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN;

CATARACT; CATARACT EXTRACTION; DIABETIC MACULAR EDEMA; EYE INFECTION; GLAUCOMA; INTRAVITREAL IMPLANT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSEUDOPHAKIA; REVIEW; RISK FACTOR; THROMBOEMBOLISM; VISUAL ACUITY; VISUAL IMPAIRMENT; VITRECTOMY;

EID: 84940044693     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622315590319     Document Type: Review

References (52)

1. Adamis A. Altaweel M. Bressler N. Cunningham E. Jr. Davis M. Goldbaum M. et al. (2006) Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 113: 23–28.
2. Agrawal R. Fernandez-Sanz G. Bala S. Addison P. (2014) Desegmentation of Ozurdex implant in vitreous cavity: report of two cases. Br J Ophthalmol 98: 961–963.
3. Bansal R. Bansal P. Kulkarni P. Gupta V. Sharma A. Gupta A. (2012) Wandering Ozurdex(®) implant. J Ophthalmic Inflamm Infect 2: 1–5.
4. Boyer D. Faber D. Gupta S. Patel S. Tabandeh H. Li X. et al. (2011) Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients. Retina 31: 915–923.
5. Boyer D. Yoon Y. Belfort R. Jr. Bandello F. Maturi R. Augustin A. et al. (2014) Three-year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology 121: 1904–1914.
6. Bressler S. Qin H. Melia M. Bressler N. Beck R. Chan C. et al. (2013) Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. J Am Med Assoc Ophthalmol 131: 1033–1040.
7. Brown D. Nguyen Q. Marcus D. Boyer D. Patel S. Feiner L. et al. (2013) Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 120: 2013–2022.
8. Bunce C. Wormald R. (2008) Causes of blind certifications in England and Wales: April 1999-March 2000. Eye (Lond) 22: 905–911.
9. Campochiaro P. Brown D. Pearson A. Chen S. Boyer D. Ruiz-Moreno J. et al. (2012) Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 119: 2125–2132.
10. Chin H. Park T. Moon Y. Oh J. (2005) Difference in clearance of intravitreal triamcinolone acetonide between vitrectomized and nonvitrectomized eyes. Retina 25: 556–560.
11. Coca-Robinot J. Casco-Silva B. Armada-Maresca F. Garcia-Martinez J. (2014) Accidental injections of dexamethasone intravitreal implant (Ozurdex) into the crystalline lens. Eur J Ophthalmol 24: 633–636.
12. Cordero-Coma M. Garzo I. Calleja S. Galan E. Franco M. Ruiz de Morales J. (2013) Preoperative cataract surgery use of an intravitreal dexamethasone implant (Ozurdex) in a patient with juvenile idiopathic arthritis and chronic anterior uveitis. J AAPOS 17: 632–634.
13. Cunha-Vaz J. Ashton P. Iezzi R. Campochiaro P. Dugel P. Holz F. et al. (2014) Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 121: 1892–1903.
14. Diabetes Control and Complications Trial Research Group (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 44: 968–983.
15. Diabetic Retinopathy Clinical Research Network (2008) A randomized trial comparing intravitreal triamcinolone acetonide and focal / grid photocoagulation for diabetic macular edema. Ophthalmology 115: 1447–1449, 1449.e1–1449.e10.
16. Diabetic Retinopathy Clinical Research Network (2015) Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 372: 1193–1203.
17. Diabetic Retinopathy Clinical Research Network, Elman M. Aiello L. Beck R. Bressler N. Bressler S. et al. (2010) Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 117: 1064–1077.e35.
18. Do D. Nguyen Q. Boyer D. Schmidt-Erfurth U. Brown D. Vitti R. et al. (2012) One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 119: 1658–1665.
19. Domalpally A. Ip M. Ehrlich J. (2015) Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 122: 779–786.
20. Eaton A. Gordon G. Booth D. Wafapoor H. Avery R. (2014) Injection force comparison of the old and new dexamethasone implant insertion needles in porcine eyes and synthetic sclera. Ophthalmic Surg Lasers Imaging Retina 45: 232–238.
21. Early Treatment Diabetic Retinopathy Study Research Group (1985) Photocoagulation for diabetic macular edema. Early treatment diabetic retinopathy study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 103: 1796–1806.
22. Gillies M. Lim L. Campain A. Quin G. Salem W. Li J. et al. (2014) A randomized clinical trial of intravitreal bevacizumab versus intravitreal dexamethasone for diabetic macular edema: the BEVORDEX study. Ophthalmology 121: 2473–2481.
23. Gillies M. Simpson J. Gaston C. Hunt G. Ali H. Zhu M. et al. (2009) Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 116: 2182–2187.
24. Gillies M. Sutter F. Simpson J. Larsson J. Ali H. Zhu M. (2006) Intravitreal triamcinolone for refractory diabetic macular edema: two-year results of a double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 113: 1533–1538.
25. Gonder J. Walker V. Barbeau M. Zaour N. Zachau B. Hartje J. et al. (2014) Costs and quality of life in diabetic macular edema: Canadian burden of diabetic macular edema observational study (C-REALITY). J Ophthalmol 2014: 939315.
26. Guigou S. Hajjar C. Parrat E. Merite P. Pommier S. Matonti F. et al. (2014) [Multicenter Ozurdex® assessment for diabetic macular edema: MOZART study]. J Fr Ophtalmol 37: 480–485.
27. Hariprasad S. Mieler W. Grassi M. Green J. Jager R. Miller L. (2008) Vision-related quality of life in patients with diabetic macular oedema. Br J Ophthalmol 92: 89–92.
28. Keech A. Mitchell P. Summanen P. O'day J. Davis T. Moffitt M. et al. (2007) Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370: 1687–1697.
29. Kiire C. Porta M. Chong V. (2013) Medical management for the prevention and treatment of diabetic macular edema. Surv Ophthalmol 58: 459–465.
30. Larsson J. Kifley A. Zhu M. Wang J. Mitchell P. Sutter F. et al. (2009) Rapid reduction of hard exudates in eyes with diabetic retinopathy after intravitreal triamcinolone: data from a randomized, placebo-controlled, clinical trial. Acta Ophthalmol 87: 275–280.
31. Lazic R. Lukic M. Boras I. Draca N. Vlasic M. Gabric N. et al. (2014) Treatment of anti-vascular endothelial growth factor-resistant diabetic macular edema with dexamethasone intravitreal implant. Retina 34: 719–724.
32. Malcles A. Janin-Manificat H. Yhuel Y. Russo A. Agard E. El Chehab H. et al. (2013) [Anterior chamber migration of intravitreal dexamethasone implant (Ozurdex®) in pseudophakic eyes: report of three cases]. J Fr Ophtalmol 36: 362–367.
33. Matthews D. Stratton I. Aldington S. Holman R. Kohner E. UK Prospective Diabetes Study Group. (2004) Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69. Arch Ophthalmol 122: 1631–1640.
34. Meyer C. Liu Z. Brinkmann C. Rodrigues E. Bertelmann T. German Retinal Vein Occlusion, Group. (2014) Penetration force, geometry, and cutting profile of the novel and old Ozurdex needle: the MONO study. J Ocul Pharmacol Ther 30: 387–391.
35. Mitchell P. Bandello F. Schmidt-Erfurth U. Lang G. Massin P. Schlingemann R. et al. (2011) The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118: 615–625.
36. Moss S. Klein R. Klein B. (1998) The 14-year incidence of visual loss in a diabetic population. Ophthalmology 105: 998–1003.
37. Nehme A. Lobenhofer E. Stamer W. Edelman J. (2009) Glucocorticoids with different chemical structures but similar glucocorticoid receptor potency regulate subsets of common and unique genes in human trabecular meshwork cells. BMC Med Genomics 2: 58.
38. Nguyen Q. Brown D. Marcus D. Boyer D. Patel S. Feiner L. et al. (2012) Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 119: 789–801.
39. Otsuka H. Kawano H. Sonoda S. Nakamura M. Sakamoto T. (2013) Particle-induced endophthalmitis: possible mechanisms of sterile endophthalmitis after intravitreal triamcinolone. Invest Ophthalmol Vis Sci 54: 1758–1766.
40. Querques G. Bux A. Martinelli D. Iaculli C. Noci N. (2009) Intravitreal pegaptanib sodium (Macugen) for diabetic macular oedema. Acta Ophthalmol 87: 623–630.
41. Rajendram R. Fraser-Bell S. Kaines A. Michaelides M. Hamilton R. Esposti S. et al. (2012) A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3. Arch Ophthalmol 130: 972–979.
42. Romero-Aroca P. Reyes-Torres J. Baget-Bernaldiz M. Blasco-Sune C. (2014) Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev 10: 100–112.
43. Simunovic M. Hunyor A. Ho I. (2014) Vitrectomy for diabetic macular edema: a systematic review and meta-analysis. Can J Ophthalmol 49: 188–195.
44. Thakur A. Kadam R. Kompella U. (2011) Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol 129: 914–920.
45. UK Prospective Diabetes Study (UKPDS) Group (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352: 837–853.
46. Virgili G. Parravano M. Menchini F. Evans J. (2014) Anti-vascular endothelial growth factor for diabetic macular oedema. Cochrane Database Syst Rev 10: CD007419.
47. Wang K. Wang Y. Gao L. Li X. Li M. Guo J. (2008) Dexamethasone inhibits leukocyte accumulation and vascular permeability in retina of streptozotocin-induced diabetic rats via reducing vascular endothelial growth factor and intercellular adhesion molecule-1 expression. Biol Pharm Bull 31: 1541–1546.
48. Whiting D. Guariguata L. Weil C. Shaw J. (2011) IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 94: 311–321.
49. Wong T. Simo R. Mitchell P. (2012) Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol 154: 6–12.
50. Yanyali A. Aytug B. Horozoglu F. Nohutcu A. (2007) Bevacizumab (Avastin) for diabetic macular edema in previously vitrectomized eyes. Am J Ophthalmol 144: 124–126.
51. Yau J. Rogers S. Kawasaki R. Lamoureux E. Kowalski J. Bek T. et al. (2012) Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 35: 556–564.
52. Zacharias L. Lin T. Migon R. Ghosn C. Orilla W. Feldmann B. et al. (2013) Assessment of the differences in pharmacokinetics and pharmacodynamics between four distinct formulations of triamcinolone acetonide. Retina 33: 522–531.